B
9.98
1.33 (15.38%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Bicara Therapeutics Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 价值 35% | 0.0 |
| AI Insight 参考 | NA |
| 相对估值 参考 | NA |
| 财务健康 参考 | 0.0 |
| 时机 35% | -1.1 |
| AI Technical 参考 | NA |
| 技术振荡指标 参考 | -2.5 |
| 技术平均移动指标 参考 | 1.0 |
| 聪明钱 30% | 0.0 |
| 分析师共识 参考 | 0.0 |
| 内部交易活动 参考 | NA |
| 市场环境 | ×1.21 |
| 宏观环境 参考 | -3.3 |
| 行业对比大市 (6个月) | -22.5% |
| 支柱一致性 | ×1.00 |
| 不计入评分 | |
| 价格波动 参考 | 3.0 |
| 最终评分 | -0.47 |
|
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 11.65% |
| 机构持股比例 | 89.28% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Red Tree Management, Llc | 30 Sep 2026 | 2,920,509 |
该时间范围内无数据。
该时间范围内无数据。
投资组合